 Stealth BioTherapeutics Corp NASDAQ: MITO has presented new data from a study evaluating SBT-272 in a murine model of Parkinsons disease PD. SBT-272 is a mitochondria-targeted product candidate, which is known to cross the blood-brain barrier. 